Why the study?
Dilated cardiomyopathy contributes importantly to global heart failure burden, and with an aging population and rising multimorbidity, the impact of metabolic syndrome and renal failure requires characterization.
Optimization of the cardio-renal-metabolic profile should be a key consideration in the management of patients with dilated cardiomyopathy to improve overall outcomes.
PURPOSE OF REVIEW: Dilated cardiomyopathy is an important contributor to heart failure burden worldwide. With an aging population and rising multimorbidity, in this review, we describe the prevalence of metabolic syndrome and renal failure in patients with dilated cardiomyopathy and focus on common underlying mechanisms, evaluate outcomes in these patients and highlight newer therapeutic strategies. RECENT FINDINGS: A significant proportion of patients with dilated cardiomyopathy has concomitant metabolic syndrome and renal disease. This combination of multimorbidity portends worse prognosis and often presents unique challenges in treatment given the complex interplay and shared pathophysiological pathways. Optimization of the cardio-renal-metabolic profile should be a key consideration in the management of patients with dilated cardiomyopathy. Therapeutic strategies targeting common pathophysiological pathways are needed in order to improve overall outcomes.
No takes yet. Share an insight, caveat, or question.
Akbari et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: